MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

120.00
+2.04
+1.73%
After Hours: 120.00 0 0.00% 16:41 01/24 EST
OPEN
118.11
PREV CLOSE
117.96
HIGH
120.78
LOW
118.01
VOLUME
894.61K
TURNOVER
--
52 WEEK HIGH
125.72
52 WEEK LOW
65.81
MARKET CAP
13.36B
P/E (TTM)
-15.4681
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALNY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALNY News

  • Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%?
  • Simply Wall St..01/16 10:29
  • Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
  • American City Business Journals.01/15 10:39
  • Drugmakers getting creative over ways to pay for pricey meds
  • Seeking Alpha - Article.01/13 17:16
  • Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
  • Zacks.01/13 15:17

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
More

Webull offers Alnylam Pharmaceuticals, Inc. (ALNY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.